由美国Tibotec公司开发的非核苷逆转录酶抑制剂rilpivirine(曾用代号TMC-278,R-278474)是一种易合成、抗病毒活性强、口服生物利用度高、安全性好的新型的二芳基嘧啶类药物。临床试验表明,rilpivirine单用(每日1次)或与其他抗逆转录病毒药物联用均有抗HIV-1感染作用,且本品不会 The non-nucleoside reverse transcriptase inhibitor rilpivirine (formerly code-named TMC-278, R-278474) developed by Tibotec Company of the United States is a new type of biodegradable, anti-viral activity, oral bioavailability and good safety Arylpyrimidines. Clinical trials have shown that rilpivirine alone (once daily) or in combination with other anti-retroviral drugs has an anti-HIV-1 infection effect and this product does not